ESC and EAS are issuing new guidelines Dyslipidaemia

The European Society of Cardiology (ESC) and the European Society of Athlete (EAS) has just published new international recommendations regarding dyslipid management. They were presented at the annual Congress of Cardiology, which took place in Madrid from August 29 to September 1, 2025.

These guidelines result from the joint efforts of international experts, conducted by Professor François Macha, head of the Cardiology Department at Geneva University Hospitals (HUG), who is the main author of this key reference document. In addition to its medical importance, this publication gives international recognition of a hug.

The new ESC/EAS recommendations update those issued in 2019, taking into account the latest results from randomized clinical trials. They are aimed at improving the assessment of cardiovascular risk and adapt the therapeutic strategies with even greater precision.

Thanks to this update, we can better identify some populations on risk and treat them more effectively. By doing so, we can better protect these men and women. “

François Mach, professor, Geneva University Hospitals

New risk assessment tools

The main progress is the introduction of two new risk algorithms, called score2 and score2 -op (for people over 70 years old). Unlike earlier models, which estimated only ten years of cardiovascular mortality, they now include end points, such as an unfathly myocardial infarction, stroke and risk of hospitalization – subject to combined incidence and mortality.

“These risk calculators are much more refined and informative. They are user -friendly and can also be used by general doctors, facilitating earlier and more targeted intervention,” explains Professor Mach.

Drug combinations

“We are lucky that we have numerous safe and effective treatment to reduce cardiovascular risk in patients such as statins. If necessary, we can combine these drugs to achieve even better results,” emphasized Dr. Konstantinos Koskinas, a cardiologist at Bern University Hospital and co -author of new recommendations.

Indeed, this update contains important explanations for treatment. After myocardial infarction or acute coronary syndrome, intensifying lipid therapy – called cholesterol and triglycerides – is now recommended since hospitalization. The combination of high -intensity therapy with Ezetimibe should immediately be considered reliable to achieve the goals of LDL -cholesterol (“bad” cholesterol). “From the very beginning we recommend a combination of agents,” says the specialist.

A new approach to the high -risk population

The update also expands the use of statins for specific groups: people living from HIV from 40 years of age and patients treated with cardiotoxic chemotherapy patterns (such as anthracyclines). These recommendations are based on recent studies that show preventive benefits in these high -risk groups.

New therapeutic options also appear for people who are statins–intolerant

The authors emphasize the need to measure lipoprotein (A), a genetically defined cardiovascular risk factor for long -minded, but now recognized as valid. It requires only one measurement, and in combination with other risk factors (LDL -cholesterol, obesity, etc.) may inform you about the consideration of new pharmacological options.

Watch out for food supplements

Finally, recommendations clearly oppose the use of dietary supplements – especially red yeast rice – and cholesterol vitamins. “These products are a significant market. But it is necessary to provide a clear message: one should not rely on these supplements to protect the heart” – insisted Professor Mach.